Welcome to our dedicated page for Volitionrx SEC filings (Ticker: VNRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The VolitionRx Limited (VNRX) SEC filings page provides direct access to the company’s U.S. regulatory disclosures, including current reports on Form 8-K, periodic reports, and registration-related documents. As a NYSE American-listed issuer, VolitionRx uses these filings to report material agreements, capital-raising transactions, governance changes, and other significant events related to its epigenetics and diagnostic testing business.
Recent Forms 8-K describe several key financing arrangements, such as an amended and restated securities purchase agreement with an institutional investor involving a senior secured convertible promissory note and common stock purchase warrant, underwritten public offerings of common stock and warrants, and a registered direct offering of shares and warrants to existing stockholders and insiders. Other 8-K filings detail amendments to the company’s certificate of incorporation to increase authorized common stock, results of stockholder votes at the annual meeting, and announcements of quarterly financial results and business updates.
These filings also outline the terms of VolitionRx’s securities, including conversion prices, warrant exercise prices, ownership limitations, repayment schedules, security interests in company assets, and conditions that constitute events of default. Investors can review how the company structures its capital, secures funding for research and commercialization of its Nu.Q® and related platforms, and manages its obligations to lenders and underwriters.
On Stock Titan, each VolitionRx filing is accompanied by AI-powered summaries that highlight the most important points, such as new financing terms, changes to authorized share capital, or disclosure of financial results. Users can quickly see which filings relate to earnings (often furnished under Item 2.02), which involve material definitive agreements (Item 1.01), and which concern governance or charter amendments (Items 5.02 and 5.03). This structure helps readers navigate lengthy documents and focus on the aspects most relevant to their analysis of VNRX.
Cameron John Reynolds, President and CEO and a director of VolitionRx Ltd (VNRX), reported an open-market purchase of common stock on 09/12/2025. He acquired 15,000 shares at $0.659 per share. After the transaction he directly beneficially owns 2,624,847 shares and indirectly owns 1,007,718 shares through Concord International, Inc.; an additional 34,076 shares are held indirectly by his spouse.
The Form 4 is signed on 09/15/2025. The filing notes Reynolds is majority shareholder of Concord International, Inc., sharing voting and dispositive control over those shares.
Terig Hughes, Chief Financial Officer and Director of VolitionRX Limited (VNRX), was awarded 26,143 restricted stock units (RSUs) on 08/15/2025 in lieu of cash compensation. The Form 4 shows the RSUs were granted at a price of $0 and the reporting person beneficially owned 533,770 shares following the award. The RSUs are earned in six approximately equal monthly installments beginning 09/01/2025 and, once earned, remain subject to additional time-based vesting in two installments of 13,072 units on 11/01/2025 and 13,071 units on 02/01/2026. The award is subject to continued service through each earning and vesting date and will settle into a like number of common shares upon vesting.
VolitionRX Ltd. (VNRX) reporting person Ann-Louise Batchelor was awarded 27,400 restricted stock units (RSUs) on 08/15/2025 under the companys 2015 Stock Incentive Plan in lieu of cash compensation. The RSUs are earned in six approximately equal monthly installments beginning 09/01/2025 and, once earned, remain subject to additional time-based vesting in two equal installments of 13,700 units on 11/01/2025 and 02/01/2026. Upon vesting and settlement each RSU converts into one share of common stock. The filing reports 159,886 shares beneficially owned directly after the transaction and 29,406 shares held indirectly by spouse. The award is conditioned on continued service through the applicable earning and vesting dates.
Rodney Gerard Rootsaert, a director and officer (Secretary) of VolitionRx Limited (VNRX), reported an award of 15,223 restricted stock units (RSUs) on 08/15/2025 issued in lieu of cash compensation. The RSUs were granted at $0 price and will be earned in six approximately equal monthly installments beginning 09/01/2025. Once earned, the RSUs remain subject to additional time-based vesting in two installments of 7,612 and 7,611 on 11/01/2025 and 02/01/2026, respectively.
The filing shows Mr. Rootsaert directly beneficially owns 149,233 common shares following the award and has indirect beneficial ownership of 1,007,718 shares held by Concord International, Inc., where he is a controlling director with shared voting and dispositive power.
VolitionRX Limited insider filing shows an award of restricted stock units and a separate disposal of shares by a reporting person. The reporting person, Salvatore Thomas Butera, was awarded 33,991 restricted stock units (RSUs) on 08/15/2025 in lieu of cash compensation; the RSUs are earned in six approximately equal monthly installments beginning 09/01/2025 and, once earned, remain subject to additional time-based vesting in two installments of 16,996 and 16,995 units on 11/01/2025 and 02/01/2026, respectively. The RSUs convert to common shares upon vesting and settlement. The filing also records a disposal of 99,350 shares of common stock that are jointly owned by the reporting person and his spouse. The reporting person is CEO - Volition Veterinary and a director of VolitionRX (VNRX).
VolitionRx Ltd. insider Andrew Retter, Chief Medical Officer and director, was awarded 19,524 restricted stock units (RSUs) on 08/15/2025 in lieu of cash compensation. The RSUs are scheduled to be earned in six approximately equal monthly installments beginning 09/01/2025 and, once earned, will remain subject to additional time-based vesting in two equal installments of 9,762 units on 11/01/2025 and 02/01/2026. The RSUs are contingent on the reporting persons continued service during the earning and vesting periods. After the award, the reporting person beneficially owns 151,156 shares of common stock as reported on the Form 4.
VolitionRX Limited insider filing (Form 4) reports that director and officer Nicholas Plummer was awarded 24,031 restricted stock units (RSUs) on 08/15/2025 in lieu of cash compensation. The RSUs are granted under the Issuer's 2015 Stock Incentive Plan, have a reported price of $0, and will be earned in six approximately equal monthly installments beginning 09/01/2025. Once earned, the awards remain subject to additional time-based vesting in two installments of 12,016 units on 11/01/2025 and 12,015 units on 02/01/2026. The filing shows 207,877 shares beneficially owned by the reporting person following the transaction.
VolitionRX Limited director Ethel Rubin was awarded 17,424 restricted stock units (RSUs) on August 15, 2025 under the companys 2015 Stock Incentive Plan in lieu of cash compensation. The RSUs are earned in six approximately equal monthly installments beginning August 1, 2025, and once earned they remain subject to further time-based vesting in two equal installments of 8,712 units on each of November 1, 2025 and February 1, 2026. Vesting and settlement will deliver common stock equal to the number of RSUs earned and vested, and continued service is generally required through each applicable earning and vesting date. Following the award, the reporting person beneficially owns 62,948 shares. The Form 4 was signed by Ethel Rubin on August 19, 2025.
VolitionRx Limited (VNRX) director Kim Nguyen was awarded 17,424 restricted stock units (RSUs) on August 15, 2025 in lieu of cash compensation under the companys 2015 Stock Incentive Plan. The RSUs are earned in six approximately equal monthly installments beginning August 1, 2025, and once earned they remain subject to additional time-based vesting in two equal installments of 8,712 units on November 1, 2025 and February 1, 2026. Upon vesting and settlement, each RSU converts to one share of common stock. After the award, the reporting person beneficially owned 115,816 shares directly and 30,556 shares indirectly (by spouse).
VolitionRX Limited director and CEO - Singapore Jasmine Kway was granted 12,507 restricted stock units (RSUs) on 08/15/2025 in lieu of cash compensation. The RSUs are earned in six approximately equal monthly installments beginning 09/01/2025 and, once earned, remain subject to additional time-based vesting in two installments of 6,254 RSUs on 11/01/2025 and 6,253 RSUs on 02/01/2026. Upon vesting and settlement, each vested RSU converts into one share of common stock. Following the award, the reporting person beneficially owns 203,614 shares, with 10,400 shares held indirectly by spouse.
FAQ
What is the current stock price of Volitionrx (VNRX)?
What is the market cap of Volitionrx (VNRX)?
